EA202190771A1 - Новое комбинированное решение для лечения рака, резистентного к химиотерапии - Google Patents
Новое комбинированное решение для лечения рака, резистентного к химиотерапииInfo
- Publication number
- EA202190771A1 EA202190771A1 EA202190771A EA202190771A EA202190771A1 EA 202190771 A1 EA202190771 A1 EA 202190771A1 EA 202190771 A EA202190771 A EA 202190771A EA 202190771 A EA202190771 A EA 202190771A EA 202190771 A1 EA202190771 A1 EA 202190771A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- resistant cancer
- combined solution
- new combined
- chemotherapy resistant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811195239 | 2018-10-12 | ||
| PCT/CN2019/110904 WO2020074010A1 (zh) | 2018-10-12 | 2019-10-12 | 治疗化疗难治性癌症的新联合用药方案 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190771A1 true EA202190771A1 (ru) | 2021-09-07 |
Family
ID=70163618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190771A EA202190771A1 (ru) | 2018-10-12 | 2019-10-12 | Новое комбинированное решение для лечения рака, резистентного к химиотерапии |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12257227B2 (https=) |
| EP (1) | EP3865130A4 (https=) |
| JP (2) | JP7513286B2 (https=) |
| CN (2) | CN120168498A (https=) |
| AU (1) | AU2019357933B2 (https=) |
| BR (1) | BR112021006898A2 (https=) |
| CA (1) | CA3115869A1 (https=) |
| EA (1) | EA202190771A1 (https=) |
| IL (1) | IL282228A (https=) |
| MX (1) | MX2021004151A (https=) |
| PH (1) | PH12021550815A1 (https=) |
| SG (1) | SG11202103707TA (https=) |
| TW (1) | TWI848990B (https=) |
| WO (1) | WO2020074010A1 (https=) |
| ZA (1) | ZA202102494B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3865130A4 (en) * | 2018-10-12 | 2022-07-20 | 1Globe Biomedical Co., Ltd. | NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050566B1 (en) | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| EP2547205B1 (en) | 2010-03-19 | 2024-03-20 | 1Globe Biomedical Co., Ltd. | Novel methods for targeting cancer stem cells |
| RU2571661C2 (ru) | 2010-03-19 | 2015-12-20 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
| US9150530B2 (en) | 2011-03-04 | 2015-10-06 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies |
| WO2013166618A1 (en) | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| EP2983790A2 (en) * | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| US20180085341A1 (en) | 2015-04-17 | 2018-03-29 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2017132049A1 (en) * | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN107766371B (zh) * | 2016-08-19 | 2023-11-17 | 中兴通讯股份有限公司 | 一种文本信息分类方法及其装置 |
| EP3865130A4 (en) * | 2018-10-12 | 2022-07-20 | 1Globe Biomedical Co., Ltd. | NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER |
-
2019
- 2019-10-12 EP EP19871382.8A patent/EP3865130A4/en active Pending
- 2019-10-12 CA CA3115869A patent/CA3115869A1/en active Pending
- 2019-10-12 BR BR112021006898-8A patent/BR112021006898A2/pt unknown
- 2019-10-12 AU AU2019357933A patent/AU2019357933B2/en active Active
- 2019-10-12 CN CN202510203958.9A patent/CN120168498A/zh active Pending
- 2019-10-12 JP JP2021520113A patent/JP7513286B2/ja active Active
- 2019-10-12 SG SG11202103707TA patent/SG11202103707TA/en unknown
- 2019-10-12 EA EA202190771A patent/EA202190771A1/ru unknown
- 2019-10-12 US US17/284,654 patent/US12257227B2/en active Active
- 2019-10-12 MX MX2021004151A patent/MX2021004151A/es unknown
- 2019-10-12 WO PCT/CN2019/110904 patent/WO2020074010A1/zh not_active Ceased
- 2019-10-12 CN CN201980066957.7A patent/CN113164438B/zh active Active
- 2019-10-14 TW TW108136944A patent/TWI848990B/zh active
-
2021
- 2021-04-11 IL IL282228A patent/IL282228A/en unknown
- 2021-04-12 PH PH12021550815A patent/PH12021550815A1/en unknown
- 2021-04-15 ZA ZA2021/02494A patent/ZA202102494B/en unknown
-
2024
- 2024-06-20 JP JP2024099957A patent/JP2024123152A/ja active Pending
-
2025
- 2025-02-25 US US19/063,086 patent/US20250235425A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120168498A (zh) | 2025-06-20 |
| US20250235425A1 (en) | 2025-07-24 |
| CN113164438B (zh) | 2025-03-18 |
| PH12021550815A1 (en) | 2021-10-04 |
| JP7513286B2 (ja) | 2024-07-09 |
| JP2024123152A (ja) | 2024-09-10 |
| JP2022504760A (ja) | 2022-01-13 |
| AU2019357933A1 (en) | 2021-05-20 |
| EP3865130A1 (en) | 2021-08-18 |
| MX2021004151A (es) | 2021-09-08 |
| BR112021006898A2 (pt) | 2021-07-20 |
| CA3115869A1 (en) | 2020-04-16 |
| EP3865130A4 (en) | 2022-07-20 |
| IL282228A (en) | 2021-05-31 |
| SG11202103707TA (en) | 2021-05-28 |
| AU2019357933B2 (en) | 2023-11-23 |
| US12257227B2 (en) | 2025-03-25 |
| US20210393571A1 (en) | 2021-12-23 |
| TW202027738A (zh) | 2020-08-01 |
| KR20210076951A (ko) | 2021-06-24 |
| TWI848990B (zh) | 2024-07-21 |
| WO2020074010A1 (zh) | 2020-04-16 |
| ZA202102494B (en) | 2023-01-25 |
| CN113164438A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| EA202191730A1 (ru) | Ингибиторы kif18a | |
| EA202091491A1 (ru) | Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1 | |
| GEP20237519B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| EA201791094A1 (ru) | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| EA201791576A1 (ru) | Ингибитор jak | |
| EA201692480A1 (ru) | Фармацевтическая композиция | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX389244B (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201792287A1 (ru) | Способы лечения рака | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза |